Eric Poeschla
Concepts (522)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunodeficiency Virus, Feline | 30 | 2023 | 33 | 7.420 |
Why?
| HIV-1 | 39 | 2022 | 836 | 4.780 |
Why?
| Genetic Vectors | 28 | 2013 | 312 | 4.330 |
Why?
| Virus Integration | 20 | 2022 | 69 | 2.970 |
Why?
| HIV Integrase | 14 | 2022 | 70 | 2.630 |
Why?
| Virus Replication | 28 | 2022 | 451 | 2.580 |
Why?
| Cats | 26 | 2023 | 208 | 2.160 |
Why?
| Intercellular Signaling Peptides and Proteins | 14 | 2022 | 375 | 2.120 |
Why?
| RNA, Viral | 13 | 2020 | 619 | 2.080 |
Why?
| Lentiviruses, Primate | 4 | 2023 | 13 | 1.940 |
Why?
| Lentivirus | 12 | 2022 | 53 | 1.900 |
Why?
| DNA, Viral | 8 | 2022 | 350 | 1.660 |
Why?
| Genetic Therapy | 13 | 2013 | 292 | 1.480 |
Why?
| Cell Line | 36 | 2020 | 2781 | 1.430 |
Why?
| Immunity, Innate | 7 | 2020 | 804 | 1.430 |
Why?
| Picornaviridae | 3 | 2020 | 17 | 1.380 |
Why?
| Interferon-Induced Helicase, IFIH1 | 2 | 2020 | 15 | 1.360 |
Why?
| Chromatin | 9 | 2016 | 479 | 1.320 |
Why?
| Reverse Transcription | 4 | 2021 | 18 | 1.160 |
Why?
| Antibodies, Viral | 2 | 2020 | 601 | 1.040 |
Why?
| Trabecular Meshwork | 9 | 2014 | 79 | 1.030 |
Why?
| RNA Interference | 8 | 2020 | 448 | 1.020 |
Why?
| Lentivirus Infections | 4 | 2014 | 7 | 1.010 |
Why?
| Retroviridae | 5 | 2022 | 99 | 0.990 |
Why?
| Aqueous Humor | 7 | 2009 | 33 | 0.960 |
Why?
| Gene Transfer Techniques | 10 | 2011 | 163 | 0.960 |
Why?
| Gene Products, gag | 3 | 2012 | 36 | 0.950 |
Why?
| Adaptor Proteins, Signal Transducing | 7 | 2020 | 399 | 0.930 |
Why?
| HIV Infections | 15 | 2022 | 2720 | 0.910 |
Why?
| Virion | 7 | 2022 | 82 | 0.900 |
Why?
| Virus Assembly | 6 | 2014 | 76 | 0.890 |
Why?
| Integrases | 5 | 2022 | 119 | 0.870 |
Why?
| Interferons | 2 | 2022 | 194 | 0.780 |
Why?
| Animals | 59 | 2023 | 35360 | 0.780 |
Why?
| Transgenes | 8 | 2009 | 177 | 0.770 |
Why?
| Capsid | 7 | 2022 | 90 | 0.760 |
Why?
| Host-Pathogen Interactions | 6 | 2021 | 352 | 0.740 |
Why?
| Molecular Sequence Data | 19 | 2014 | 2832 | 0.710 |
Why?
| Spumavirus | 1 | 2020 | 2 | 0.710 |
Why?
| Gammaretrovirus | 1 | 2020 | 2 | 0.710 |
Why?
| Recombinant Fusion Proteins | 6 | 2011 | 643 | 0.680 |
Why?
| Teicoplanin | 1 | 2020 | 15 | 0.670 |
Why?
| HIV | 6 | 2012 | 226 | 0.660 |
Why?
| Chiroptera | 1 | 2020 | 53 | 0.660 |
Why?
| Transcription Factors | 7 | 2020 | 1651 | 0.650 |
Why?
| Prisons | 1 | 2020 | 79 | 0.640 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2020 | 67 | 0.640 |
Why?
| Antibodies, Neutralizing | 2 | 2022 | 265 | 0.640 |
Why?
| Liver Diseases, Parasitic | 1 | 2019 | 2 | 0.630 |
Why?
| Fascioliasis | 1 | 2019 | 6 | 0.630 |
Why?
| Humans | 98 | 2023 | 129622 | 0.620 |
Why?
| Pneumonia, Viral | 2 | 2020 | 341 | 0.610 |
Why?
| Coronavirus Infections | 2 | 2020 | 335 | 0.600 |
Why?
| Nucleotidyltransferases | 1 | 2018 | 27 | 0.600 |
Why?
| Exodeoxyribonucleases | 1 | 2018 | 24 | 0.600 |
Why?
| Retroviridae Infections | 3 | 2020 | 46 | 0.590 |
Why?
| CD4-Positive T-Lymphocytes | 5 | 2014 | 1056 | 0.590 |
Why?
| Amino Acid Sequence | 10 | 2023 | 2058 | 0.580 |
Why?
| Betacoronavirus | 1 | 2020 | 249 | 0.560 |
Why?
| Ferrets | 2 | 2020 | 25 | 0.550 |
Why?
| Dyspnea | 1 | 2019 | 242 | 0.540 |
Why?
| Transformation, Genetic | 2 | 2012 | 15 | 0.530 |
Why?
| Outpatients | 1 | 2020 | 370 | 0.530 |
Why?
| Eosinophilia | 1 | 2019 | 204 | 0.520 |
Why?
| Phosphoproteins | 1 | 2018 | 332 | 0.510 |
Why?
| mRNA Cleavage and Polyadenylation Factors | 4 | 2020 | 27 | 0.500 |
Why?
| Viral Load | 3 | 2020 | 448 | 0.490 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 1367 | 0.480 |
Why?
| Nuclear Pore Complex Proteins | 2 | 2020 | 36 | 0.480 |
Why?
| Pandemics | 2 | 2020 | 1486 | 0.470 |
Why?
| Gene Knockout Techniques | 2 | 2014 | 109 | 0.460 |
Why?
| DNA, Complementary | 2 | 2013 | 270 | 0.460 |
Why?
| Cat Diseases | 1 | 2014 | 19 | 0.440 |
Why?
| Cytosine Deaminase | 2 | 2010 | 15 | 0.430 |
Why?
| HIV Integrase Inhibitors | 4 | 2022 | 69 | 0.420 |
Why?
| Viral Envelope Proteins | 1 | 2014 | 81 | 0.420 |
Why?
| Transduction, Genetic | 5 | 2008 | 128 | 0.420 |
Why?
| Glaucoma | 2 | 2009 | 219 | 0.410 |
Why?
| Animals, Genetically Modified | 2 | 2011 | 229 | 0.400 |
Why?
| Molecular Chaperones | 1 | 2014 | 182 | 0.390 |
Why?
| Lentiviruses, Feline | 1 | 2011 | 1 | 0.370 |
Why?
| Carnivora | 1 | 2011 | 6 | 0.370 |
Why?
| Intraocular Pressure | 3 | 2009 | 297 | 0.370 |
Why?
| Primate Diseases | 1 | 2011 | 4 | 0.370 |
Why?
| RNA-Binding Proteins | 2 | 2014 | 388 | 0.370 |
Why?
| Open Reading Frames | 1 | 2012 | 117 | 0.370 |
Why?
| Monkey Diseases | 1 | 2011 | 20 | 0.370 |
Why?
| Transfection | 7 | 2012 | 911 | 0.370 |
Why?
| Nuclear Localization Signals | 3 | 2006 | 15 | 0.360 |
Why?
| Base Sequence | 11 | 2012 | 2142 | 0.360 |
Why?
| Cells, Cultured | 10 | 2012 | 4083 | 0.360 |
Why?
| Mice | 19 | 2020 | 16937 | 0.360 |
Why?
| Antigens, CD | 1 | 2014 | 489 | 0.360 |
Why?
| Mutation | 9 | 2020 | 3717 | 0.360 |
Why?
| Cell Nucleus | 5 | 2021 | 582 | 0.350 |
Why?
| Green Fluorescent Proteins | 7 | 2011 | 385 | 0.350 |
Why?
| Gene Products, vif | 1 | 2010 | 2 | 0.350 |
Why?
| Gene Expression | 9 | 2013 | 1472 | 0.340 |
Why?
| Nerve Tissue Proteins | 1 | 2014 | 570 | 0.340 |
Why?
| Luminescent Proteins | 4 | 2012 | 175 | 0.340 |
Why?
| Cytidine Deaminase | 1 | 2010 | 57 | 0.340 |
Why?
| Active Transport, Cell Nucleus | 6 | 2022 | 113 | 0.340 |
Why?
| Anti-Bacterial Agents | 1 | 2020 | 1717 | 0.330 |
Why?
| DNA Viruses | 1 | 2009 | 11 | 0.330 |
Why?
| Disease Models, Animal | 5 | 2013 | 4063 | 0.330 |
Why?
| Prostaglandins | 1 | 2009 | 93 | 0.330 |
Why?
| Purines | 1 | 2010 | 172 | 0.320 |
Why?
| Eye Proteins | 4 | 2014 | 88 | 0.320 |
Why?
| Gene Knockdown Techniques | 2 | 2016 | 315 | 0.320 |
Why?
| beta-Galactosidase | 3 | 2004 | 77 | 0.310 |
Why?
| RNA, Messenger | 5 | 2023 | 2708 | 0.300 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2009 | 148 | 0.290 |
Why?
| Cytoplasm | 5 | 2021 | 263 | 0.290 |
Why?
| HIV-2 | 5 | 2002 | 18 | 0.290 |
Why?
| Biological Evolution | 1 | 2011 | 427 | 0.290 |
Why?
| Primates | 3 | 2020 | 120 | 0.280 |
Why?
| Retina | 3 | 2004 | 279 | 0.270 |
Why?
| HEK293 Cells | 5 | 2020 | 697 | 0.270 |
Why?
| Antiviral Agents | 3 | 2022 | 712 | 0.260 |
Why?
| Gene Targeting | 2 | 2004 | 82 | 0.250 |
Why?
| Mice, Transgenic | 3 | 2020 | 2119 | 0.250 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 7 | 0.250 |
Why?
| Proteins | 3 | 2007 | 942 | 0.240 |
Why?
| Protein Binding | 8 | 2021 | 2121 | 0.240 |
Why?
| Anti-HIV Agents | 2 | 2022 | 754 | 0.230 |
Why?
| Oncogenic Viruses | 1 | 2004 | 3 | 0.230 |
Why?
| Genes, Reporter | 4 | 2012 | 267 | 0.230 |
Why?
| HeLa Cells | 7 | 2020 | 608 | 0.230 |
Why?
| Genome, Viral | 5 | 2019 | 129 | 0.230 |
Why?
| Cell Culture Techniques | 3 | 2012 | 345 | 0.220 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 958 | 0.220 |
Why?
| Terminal Repeat Sequences | 2 | 2020 | 15 | 0.220 |
Why?
| Lymphocytes | 4 | 2012 | 377 | 0.220 |
Why?
| Pigment Epithelium of Eye | 1 | 2003 | 34 | 0.220 |
Why?
| Emigration and Immigration | 2 | 2020 | 50 | 0.220 |
Why?
| Acquired Immunodeficiency Syndrome | 2 | 1996 | 227 | 0.220 |
Why?
| Anti-Retroviral Agents | 1 | 2005 | 231 | 0.210 |
Why?
| Protein Structure, Tertiary | 5 | 2015 | 840 | 0.210 |
Why?
| Bone Marrow Stromal Antigen 2 | 1 | 2023 | 2 | 0.210 |
Why?
| Human Immunodeficiency Virus Proteins | 1 | 2023 | 6 | 0.210 |
Why?
| Protein Sorting Signals | 1 | 2023 | 19 | 0.210 |
Why?
| Evolution, Molecular | 3 | 2020 | 466 | 0.210 |
Why?
| Viral Regulatory and Accessory Proteins | 1 | 2023 | 27 | 0.210 |
Why?
| Amino Acids | 2 | 2023 | 485 | 0.210 |
Why?
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 108 | 0.210 |
Why?
| GPI-Linked Proteins | 1 | 2023 | 68 | 0.200 |
Why?
| RNA, Catalytic | 5 | 1998 | 185 | 0.200 |
Why?
| Caveolins | 1 | 2002 | 5 | 0.200 |
Why?
| Mutation, Missense | 2 | 2014 | 317 | 0.200 |
Why?
| RNA, Small Interfering | 2 | 2020 | 587 | 0.200 |
Why?
| Paragonimiasis | 1 | 2002 | 2 | 0.200 |
Why?
| Paragonimus | 1 | 2002 | 2 | 0.200 |
Why?
| Cytoskeletal Proteins | 3 | 2008 | 146 | 0.200 |
Why?
| Karyopherins | 2 | 2012 | 19 | 0.200 |
Why?
| Gene Products, env | 3 | 2012 | 6 | 0.200 |
Why?
| Endemic Diseases | 1 | 2002 | 31 | 0.190 |
Why?
| Aotidae | 2 | 2020 | 7 | 0.190 |
Why?
| Genetic Engineering | 1 | 2003 | 88 | 0.190 |
Why?
| Saliva | 1 | 2023 | 209 | 0.190 |
Why?
| Tripartite Motif Proteins | 2 | 2020 | 29 | 0.190 |
Why?
| Virus Cultivation | 2 | 2012 | 28 | 0.190 |
Why?
| Cytomegalovirus | 3 | 2012 | 154 | 0.190 |
Why?
| Promoter Regions, Genetic | 4 | 2012 | 1207 | 0.190 |
Why?
| Dogs | 2 | 2014 | 381 | 0.180 |
Why?
| Glycoproteins | 3 | 2008 | 338 | 0.180 |
Why?
| Viral Proteins | 3 | 2015 | 328 | 0.180 |
Why?
| Genes, Viral | 2 | 2015 | 82 | 0.180 |
Why?
| Cyclophilin A | 1 | 2020 | 26 | 0.170 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2012 | 217 | 0.170 |
Why?
| 3T3 Cells | 1 | 2020 | 153 | 0.170 |
Why?
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 7 | 0.170 |
Why?
| Plasmids | 5 | 2012 | 358 | 0.170 |
Why?
| Drug Resistance, Viral | 2 | 2014 | 110 | 0.170 |
Why?
| Immunologic Surveillance | 1 | 2020 | 26 | 0.170 |
Why?
| Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
| Vesicular Transport Proteins | 1 | 2021 | 84 | 0.170 |
Why?
| Disease Resistance | 1 | 2020 | 31 | 0.170 |
Why?
| Quarantine | 1 | 2020 | 27 | 0.170 |
Why?
| Receptor, Interferon alpha-beta | 1 | 2020 | 33 | 0.170 |
Why?
| Growth Inhibitors | 2 | 2013 | 44 | 0.170 |
Why?
| RNA Virus Infections | 1 | 2019 | 13 | 0.160 |
Why?
| Interferon-beta | 1 | 2020 | 89 | 0.160 |
Why?
| Immune Evasion | 1 | 2020 | 56 | 0.160 |
Why?
| Immunoassay | 1 | 2020 | 107 | 0.160 |
Why?
| RNA, Double-Stranded | 1 | 2019 | 47 | 0.160 |
Why?
| Immunoblotting | 2 | 2014 | 305 | 0.160 |
Why?
| Ciliary Body | 2 | 2009 | 33 | 0.160 |
Why?
| Endogenous Retroviruses | 1 | 2020 | 34 | 0.160 |
Why?
| RNA Viruses | 1 | 2019 | 34 | 0.160 |
Why?
| Immunity, Humoral | 1 | 2020 | 118 | 0.160 |
Why?
| Embryonic Development | 1 | 2020 | 114 | 0.160 |
Why?
| Delayed-Action Preparations | 1 | 2020 | 173 | 0.160 |
Why?
| Viremia | 1 | 2020 | 131 | 0.160 |
Why?
| Interferon Type I | 1 | 2020 | 139 | 0.160 |
Why?
| Sequence Alignment | 2 | 2014 | 332 | 0.160 |
Why?
| Afghanistan | 1 | 2019 | 70 | 0.150 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2020 | 821 | 0.150 |
Why?
| Cell Transformation, Viral | 1 | 1998 | 27 | 0.150 |
Why?
| THP-1 Cells | 1 | 2018 | 22 | 0.150 |
Why?
| Monocytes | 2 | 2018 | 551 | 0.150 |
Why?
| Emigrants and Immigrants | 1 | 2020 | 122 | 0.150 |
Why?
| Receptors, CXCR4 | 1 | 1998 | 83 | 0.150 |
Why?
| Transcription, Genetic | 4 | 2016 | 1418 | 0.140 |
Why?
| Renal Insufficiency | 1 | 2020 | 149 | 0.140 |
Why?
| Genes, vif | 2 | 2010 | 3 | 0.140 |
Why?
| Residence Characteristics | 1 | 2020 | 328 | 0.140 |
Why?
| Protein Transport | 2 | 2012 | 428 | 0.140 |
Why?
| T-Lymphocytes | 5 | 2020 | 1928 | 0.140 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 247 | 0.140 |
Why?
| Rats | 7 | 2014 | 5499 | 0.140 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2020 | 396 | 0.130 |
Why?
| Genes, Immediate-Early | 2 | 2012 | 20 | 0.130 |
Why?
| Quinolines | 2 | 2014 | 156 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 487 | 0.130 |
Why?
| Kinetics | 6 | 2013 | 1642 | 0.120 |
Why?
| Public Health | 1 | 2020 | 484 | 0.120 |
Why?
| Blotting, Western | 5 | 2015 | 1205 | 0.120 |
Why?
| Species Specificity | 2 | 2012 | 575 | 0.120 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 613 | 0.120 |
Why?
| Echinocandins | 1 | 2014 | 7 | 0.120 |
Why?
| Gene Products, rev | 2 | 2004 | 6 | 0.110 |
Why?
| Female | 15 | 2020 | 68770 | 0.110 |
Why?
| Amphotericin B | 1 | 2014 | 29 | 0.110 |
Why?
| Mucormycosis | 1 | 2014 | 22 | 0.110 |
Why?
| Voriconazole | 1 | 2014 | 20 | 0.110 |
Why?
| rhoA GTP-Binding Protein | 1 | 2014 | 89 | 0.110 |
Why?
| Healthcare Disparities | 1 | 2020 | 578 | 0.110 |
Why?
| Gene Expression Regulation | 1 | 2003 | 2548 | 0.110 |
Why?
| Acetates | 1 | 2014 | 100 | 0.110 |
Why?
| Organ Culture Techniques | 3 | 2006 | 154 | 0.110 |
Why?
| Sequence Deletion | 2 | 2006 | 179 | 0.110 |
Why?
| Genes, gag | 2 | 2004 | 4 | 0.110 |
Why?
| Ocular Hypertension | 1 | 2014 | 66 | 0.110 |
Why?
| Polymerase Chain Reaction | 2 | 2014 | 1038 | 0.110 |
Why?
| Cyclophilins | 1 | 2014 | 41 | 0.110 |
Why?
| Antifungal Agents | 1 | 2014 | 129 | 0.110 |
Why?
| Introns | 3 | 2015 | 251 | 0.100 |
Why?
| Retroviridae Proteins | 2 | 2012 | 11 | 0.100 |
Why?
| Protein Multimerization | 1 | 2014 | 179 | 0.100 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 2406 | 0.100 |
Why?
| Mice, Knockout | 3 | 2015 | 2871 | 0.100 |
Why?
| Vero Cells | 2 | 2019 | 65 | 0.100 |
Why?
| F-Box Proteins | 1 | 2012 | 26 | 0.100 |
Why?
| Microscopy, Confocal | 2 | 2004 | 310 | 0.100 |
Why?
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 11 | 0.100 |
Why?
| Collagen | 1 | 2014 | 434 | 0.100 |
Why?
| DNA-Binding Proteins | 3 | 2013 | 1443 | 0.100 |
Why?
| Genes, env | 1 | 2012 | 4 | 0.100 |
Why?
| Male | 13 | 2020 | 63674 | 0.100 |
Why?
| Genes, Synthetic | 1 | 2012 | 14 | 0.100 |
Why?
| Mink | 1 | 2011 | 12 | 0.100 |
Why?
| Mice, Inbred C57BL | 2 | 2020 | 5440 | 0.100 |
Why?
| Feline Acquired Immunodeficiency Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
| Rabbits | 2 | 2011 | 778 | 0.090 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 15 | 0.090 |
Why?
| Caspase 8 | 1 | 2011 | 48 | 0.090 |
Why?
| DNA | 3 | 2005 | 1400 | 0.090 |
Why?
| Histidine | 2 | 2014 | 60 | 0.090 |
Why?
| bcl-2-Associated X Protein | 1 | 2011 | 55 | 0.090 |
Why?
| Jurkat Cells | 3 | 2020 | 134 | 0.090 |
Why?
| APOBEC-3G Deaminase | 1 | 2010 | 5 | 0.090 |
Why?
| Signal Transduction | 2 | 2020 | 4925 | 0.090 |
Why?
| Macrophages | 3 | 2009 | 1480 | 0.090 |
Why?
| Antigens, Neoplasm | 1 | 2013 | 309 | 0.090 |
Why?
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.090 |
Why?
| Injections | 2 | 2009 | 174 | 0.090 |
Why?
| Virus Internalization | 1 | 2010 | 47 | 0.080 |
Why?
| Polyradiculoneuropathy | 1 | 2009 | 3 | 0.080 |
Why?
| Swine | 2 | 2009 | 760 | 0.080 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 24 | 0.080 |
Why?
| Isoenzymes | 1 | 2010 | 302 | 0.080 |
Why?
| Neoplasms | 2 | 2013 | 2470 | 0.080 |
Why?
| Iris | 1 | 2009 | 19 | 0.080 |
Why?
| Macaca fascicularis | 1 | 2009 | 62 | 0.080 |
Why?
| Young Adult | 4 | 2020 | 12426 | 0.080 |
Why?
| Cyclooxygenase 2 | 1 | 2009 | 177 | 0.080 |
Why?
| Endosomes | 1 | 2010 | 126 | 0.080 |
Why?
| Gene Deletion | 2 | 2002 | 379 | 0.080 |
Why?
| Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| Protein Processing, Post-Translational | 2 | 2004 | 455 | 0.080 |
Why?
| Recombinant Proteins | 2 | 2009 | 1304 | 0.080 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 532 | 0.080 |
Why?
| Antigens, Viral | 1 | 2009 | 178 | 0.080 |
Why?
| Cell Division | 2 | 2001 | 797 | 0.070 |
Why?
| United States | 3 | 2020 | 13900 | 0.070 |
Why?
| Infectious Anemia Virus, Equine | 1 | 2007 | 1 | 0.070 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2007 | 153 | 0.070 |
Why?
| Occupational Diseases | 1 | 2009 | 138 | 0.070 |
Why?
| rev Gene Products, Human Immunodeficiency Virus | 2 | 2004 | 6 | 0.070 |
Why?
| RNA Splicing | 2 | 2015 | 262 | 0.070 |
Why?
| Glaucoma, Open-Angle | 1 | 2009 | 101 | 0.070 |
Why?
| Cell Membrane | 3 | 2010 | 732 | 0.070 |
Why?
| Antigens, CD34 | 2 | 1998 | 88 | 0.070 |
Why?
| Phylogeny | 1 | 2011 | 852 | 0.070 |
Why?
| Leukocytes, Mononuclear | 1 | 2010 | 545 | 0.070 |
Why?
| Gene Products, pol | 2 | 1998 | 6 | 0.070 |
Why?
| Models, Genetic | 1 | 2009 | 594 | 0.070 |
Why?
| Virulence | 1 | 2007 | 255 | 0.070 |
Why?
| Crystallography, X-Ray | 2 | 2020 | 436 | 0.070 |
Why?
| Binding Sites | 2 | 2021 | 1252 | 0.070 |
Why?
| Defective Viruses | 2 | 2004 | 5 | 0.070 |
Why?
| Chromosomes, Human | 1 | 2006 | 41 | 0.060 |
Why?
| Time Factors | 2 | 2009 | 6556 | 0.060 |
Why?
| Occupational Exposure | 1 | 2009 | 299 | 0.060 |
Why?
| Retinal Ganglion Cells | 2 | 2004 | 97 | 0.060 |
Why?
| Oxidative Stress | 1 | 2012 | 1269 | 0.060 |
Why?
| Models, Biological | 1 | 2013 | 1722 | 0.060 |
Why?
| Image Processing, Computer-Assisted | 1 | 2010 | 744 | 0.060 |
Why?
| Aged | 6 | 2020 | 22099 | 0.060 |
Why?
| Cell Survival | 1 | 2009 | 1086 | 0.060 |
Why?
| Avian Leukosis Virus | 1 | 2005 | 6 | 0.060 |
Why?
| Peptide Fragments | 1 | 2009 | 692 | 0.060 |
Why?
| Genes, Regulator | 1 | 2005 | 34 | 0.060 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 341 | 0.060 |
Why?
| Leukemia Virus, Gibbon Ape | 1 | 2005 | 1 | 0.060 |
Why?
| Mitochondria | 1 | 2011 | 877 | 0.060 |
Why?
| NIH 3T3 Cells | 1 | 2005 | 141 | 0.060 |
Why?
| Proteasome Inhibitors | 1 | 2004 | 42 | 0.060 |
Why?
| Ribonucleases | 1 | 2004 | 54 | 0.060 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 267 | 0.060 |
Why?
| Nuclear Proteins | 1 | 2009 | 663 | 0.060 |
Why?
| Ubiquitin | 1 | 2004 | 64 | 0.060 |
Why?
| Indicators and Reagents | 1 | 2004 | 109 | 0.060 |
Why?
| Genes, vpu | 1 | 2004 | 1 | 0.060 |
Why?
| Immunoprecipitation | 1 | 2004 | 157 | 0.060 |
Why?
| Hematopoietic Stem Cells | 2 | 1998 | 381 | 0.060 |
Why?
| Histones | 1 | 2009 | 588 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2282 | 0.060 |
Why?
| Protease Inhibitors | 1 | 2004 | 106 | 0.050 |
Why?
| Models, Molecular | 2 | 2022 | 1492 | 0.050 |
Why?
| Alleles | 2 | 2020 | 845 | 0.050 |
Why?
| Digestive System Diseases | 1 | 2003 | 25 | 0.050 |
Why?
| Carrier Proteins | 1 | 2007 | 743 | 0.050 |
Why?
| Gene Expression Regulation, Viral | 1 | 2004 | 90 | 0.050 |
Why?
| Adenoviridae | 1 | 2004 | 192 | 0.050 |
Why?
| Codon, Initiator | 1 | 2002 | 9 | 0.050 |
Why?
| Microscopy, Fluorescence | 1 | 2004 | 400 | 0.050 |
Why?
| Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| Proviruses | 1 | 2002 | 12 | 0.050 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 287 | 0.050 |
Why?
| Virus Uncoating | 1 | 2022 | 1 | 0.050 |
Why?
| Eye Diseases | 1 | 2003 | 81 | 0.050 |
Why?
| Caveolin 1 | 1 | 2002 | 19 | 0.050 |
Why?
| Laos | 1 | 2002 | 4 | 0.050 |
Why?
| Immunoenzyme Techniques | 1 | 2002 | 213 | 0.050 |
Why?
| Apoptosis | 1 | 2011 | 2503 | 0.050 |
Why?
| Aphidicolin | 1 | 2001 | 5 | 0.050 |
Why?
| Cell Cycle | 1 | 2005 | 592 | 0.050 |
Why?
| Respiratory Tract Diseases | 1 | 2003 | 148 | 0.050 |
Why?
| Leukemia Virus, Murine | 1 | 2001 | 17 | 0.050 |
Why?
| Lac Operon | 1 | 2001 | 45 | 0.050 |
Why?
| Capsid Proteins | 1 | 2022 | 90 | 0.050 |
Why?
| Genetic Markers | 1 | 2002 | 338 | 0.050 |
Why?
| Fluorescent Antibody Technique | 1 | 2002 | 376 | 0.050 |
Why?
| Chromosome Mapping | 1 | 2002 | 504 | 0.050 |
Why?
| Nuclear Pore | 1 | 2021 | 16 | 0.050 |
Why?
| Catalytic Domain | 1 | 2022 | 218 | 0.050 |
Why?
| Osteoblasts | 1 | 2002 | 124 | 0.040 |
Why?
| Organ Specificity | 1 | 2001 | 296 | 0.040 |
Why?
| Middle Aged | 6 | 2020 | 31150 | 0.040 |
Why?
| Deuterium Exchange Measurement | 1 | 2020 | 29 | 0.040 |
Why?
| Acute Disease | 1 | 2023 | 980 | 0.040 |
Why?
| Nervous System Diseases | 1 | 2003 | 252 | 0.040 |
Why?
| Amino Acid Motifs | 1 | 2021 | 213 | 0.040 |
Why?
| Breast Neoplasms | 1 | 2012 | 2142 | 0.040 |
Why?
| Nuclear Respiratory Factor 1 | 1 | 2020 | 3 | 0.040 |
Why?
| Phenotype | 2 | 2013 | 3076 | 0.040 |
Why?
| Horses | 1 | 2020 | 107 | 0.040 |
Why?
| Macaca mulatta | 1 | 2020 | 149 | 0.040 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 17 | 0.040 |
Why?
| HCT116 Cells | 1 | 2020 | 78 | 0.040 |
Why?
| Travel | 1 | 2020 | 122 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2021 | 548 | 0.040 |
Why?
| Proteinuria | 1 | 2020 | 91 | 0.040 |
Why?
| Cryoelectron Microscopy | 1 | 2020 | 178 | 0.040 |
Why?
| Sheep | 1 | 2022 | 837 | 0.040 |
Why?
| Neurons | 2 | 1998 | 1511 | 0.040 |
Why?
| Nucleic Acid Conformation | 1 | 2002 | 706 | 0.040 |
Why?
| Immunohistochemistry | 2 | 2015 | 1698 | 0.040 |
Why?
| Protein Domains | 1 | 2020 | 253 | 0.040 |
Why?
| Giant Cells | 1 | 1998 | 23 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2001 | 779 | 0.040 |
Why?
| Rodentia | 1 | 1998 | 49 | 0.040 |
Why?
| Needs Assessment | 1 | 2020 | 360 | 0.040 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| Aged, 80 and over | 3 | 2008 | 7084 | 0.040 |
Why?
| Drug Therapy, Combination | 2 | 2014 | 1040 | 0.040 |
Why?
| Health Status Disparities | 1 | 2020 | 254 | 0.040 |
Why?
| Cattle | 1 | 2020 | 976 | 0.040 |
Why?
| Coculture Techniques | 1 | 1998 | 226 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 111 | 0.040 |
Why?
| Mutagenesis | 1 | 1998 | 181 | 0.040 |
Why?
| Brain | 1 | 2009 | 2679 | 0.030 |
Why?
| Age Factors | 1 | 2003 | 3144 | 0.030 |
Why?
| RNA | 1 | 2022 | 883 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1434 | 0.030 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2020 | 704 | 0.030 |
Why?
| In Situ Hybridization | 1 | 2015 | 295 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 607 | 0.030 |
Why?
| AIDS Vaccines | 1 | 1995 | 47 | 0.030 |
Why?
| Cell Line, Tumor | 2 | 2013 | 3215 | 0.030 |
Why?
| Mutant Proteins | 1 | 2014 | 99 | 0.030 |
Why?
| Receptors, Purinergic | 3 | 1990 | 23 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 331 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2014 | 282 | 0.030 |
Why?
| Vesicular stomatitis Indiana virus | 1 | 2013 | 13 | 0.030 |
Why?
| History, 21st Century | 1 | 2014 | 183 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 769 | 0.030 |
Why?
| Topoisomerase II Inhibitors | 1 | 2013 | 24 | 0.030 |
Why?
| DNA Topoisomerases, Type II | 1 | 2013 | 43 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 833 | 0.030 |
Why?
| Virus Diseases | 1 | 2015 | 211 | 0.030 |
Why?
| Galactose | 1 | 2013 | 28 | 0.030 |
Why?
| Tumor Escape | 1 | 2013 | 39 | 0.030 |
Why?
| Fungi | 1 | 2014 | 136 | 0.030 |
Why?
| Gene Library | 1 | 2013 | 116 | 0.030 |
Why?
| Succinate Dehydrogenase | 1 | 2013 | 44 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 119 | 0.030 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2012 | 150 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2013 | 123 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 171 | 0.020 |
Why?
| Serine-Arginine Splicing Factors | 1 | 2012 | 22 | 0.020 |
Why?
| Biomarkers | 1 | 2023 | 3973 | 0.020 |
Why?
| Receptors, Cell Surface | 2 | 1984 | 380 | 0.020 |
Why?
| Molecular Conformation | 1 | 2012 | 144 | 0.020 |
Why?
| Paraganglioma | 1 | 2013 | 49 | 0.020 |
Why?
| Immunotherapy | 2 | 2013 | 592 | 0.020 |
Why?
| Protein Conformation | 1 | 2014 | 859 | 0.020 |
Why?
| DNA Primers | 1 | 2012 | 510 | 0.020 |
Why?
| Immunotherapy, Adoptive | 1 | 1995 | 295 | 0.020 |
Why?
| Doxorubicin | 1 | 2013 | 325 | 0.020 |
Why?
| Caspase 9 | 1 | 2011 | 56 | 0.020 |
Why?
| Cardiovascular Diseases | 1 | 2003 | 2004 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 3240 | 0.020 |
Why?
| Epitopes | 1 | 2013 | 470 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2011 | 426 | 0.020 |
Why?
| Adenosine | 2 | 1990 | 227 | 0.020 |
Why?
| Salt Gland | 1 | 1990 | 1 | 0.020 |
Why?
| Adipose Tissue | 2 | 1984 | 592 | 0.020 |
Why?
| Abattoirs | 1 | 2009 | 2 | 0.020 |
Why?
| Recurrence | 1 | 2013 | 1007 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 1995 | 1004 | 0.020 |
Why?
| Myelin Basic Protein | 1 | 2009 | 45 | 0.020 |
Why?
| Indiana | 1 | 2009 | 33 | 0.020 |
Why?
| Colorado | 1 | 2020 | 4420 | 0.020 |
Why?
| Air Pollutants, Occupational | 1 | 2009 | 32 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 827 | 0.020 |
Why?
| Chlorides | 1 | 1990 | 139 | 0.020 |
Why?
| Minnesota | 1 | 2009 | 149 | 0.020 |
Why?
| Cyclic AMP | 1 | 1990 | 237 | 0.020 |
Why?
| Models, Theoretical | 1 | 2013 | 547 | 0.020 |
Why?
| Demyelinating Diseases | 1 | 2009 | 84 | 0.020 |
Why?
| Repressor Proteins | 1 | 2012 | 406 | 0.020 |
Why?
| Inhalation Exposure | 1 | 2009 | 91 | 0.020 |
Why?
| Aerosols | 1 | 2009 | 170 | 0.020 |
Why?
| Binding Sites, Antibody | 1 | 2008 | 42 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2012 | 586 | 0.020 |
Why?
| Adult | 3 | 2020 | 35572 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 1 | 2013 | 759 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2008 | 110 | 0.020 |
Why?
| Hybridomas | 1 | 2008 | 234 | 0.020 |
Why?
| Antibody Specificity | 1 | 2008 | 184 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2009 | 4896 | 0.020 |
Why?
| Consensus Sequence | 1 | 2007 | 72 | 0.020 |
Why?
| Eye | 1 | 2008 | 104 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 1156 | 0.020 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2006 | 11 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2009 | 349 | 0.020 |
Why?
| Melanoma | 1 | 2013 | 730 | 0.020 |
Why?
| HIV Protease Inhibitors | 1 | 2006 | 68 | 0.020 |
Why?
| Microarray Analysis | 1 | 2005 | 122 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2013 | 1016 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2008 | 1245 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 340 | 0.020 |
Why?
| Clinical Protocols | 2 | 1998 | 255 | 0.010 |
Why?
| Ethylmaleimide | 1 | 1984 | 18 | 0.010 |
Why?
| Gene Silencing | 1 | 2005 | 190 | 0.010 |
Why?
| Guanine Nucleotides | 1 | 1984 | 15 | 0.010 |
Why?
| Codon | 1 | 2004 | 86 | 0.010 |
Why?
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2002 | 1 | 0.010 |
Why?
| Hypophosphatemia, Familial | 1 | 2002 | 3 | 0.010 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2002 | 26 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 2012 | 0.010 |
Why?
| Autoantibodies | 1 | 2009 | 1466 | 0.010 |
Why?
| Growth Plate | 1 | 2002 | 36 | 0.010 |
Why?
| Golgi Apparatus | 1 | 2002 | 100 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2002 | 406 | 0.010 |
Why?
| Vitreous Body | 1 | 2002 | 108 | 0.010 |
Why?
| Blood Platelets | 1 | 1984 | 380 | 0.010 |
Why?
| Skull | 1 | 2002 | 129 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 20391 | 0.010 |
Why?
| In Vitro Techniques | 3 | 1990 | 1085 | 0.010 |
Why?
| Animals, Newborn | 1 | 2002 | 835 | 0.010 |
Why?
| Endoplasmic Reticulum | 1 | 2002 | 261 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 1998 | 20 | 0.010 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 1998 | 50 | 0.010 |
Why?
| Adenylyl Cyclases | 2 | 1990 | 83 | 0.010 |
Why?
| Skin | 1 | 2002 | 725 | 0.010 |
Why?
| Phenylisopropyladenosine | 2 | 1984 | 6 | 0.010 |
Why?
| RNA Polymerase III | 1 | 1994 | 26 | 0.010 |
Why?
| Hydrolysis | 1 | 1995 | 186 | 0.010 |
Why?
| Gentamicins | 1 | 1994 | 54 | 0.010 |
Why?
| RNA, Antisense | 1 | 1994 | 15 | 0.010 |
Why?
| Drug Resistance | 1 | 1994 | 166 | 0.010 |
Why?
| Selection, Genetic | 1 | 1994 | 249 | 0.010 |
Why?
| Treatment Outcome | 1 | 2006 | 10226 | 0.010 |
Why?
| 2-Chloroadenosine | 1 | 1990 | 3 | 0.010 |
Why?
| Dogfish | 1 | 1990 | 4 | 0.010 |
Why?
| Colforsin | 1 | 1990 | 50 | 0.010 |
Why?
| Somatostatin | 1 | 1990 | 55 | 0.010 |
Why?
| Theophylline | 1 | 1990 | 68 | 0.010 |
Why?
| Perfusion | 1 | 1990 | 197 | 0.000 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 1994 | 573 | 0.000 |
Why?
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1984 | 11 | 0.000 |
Why?
| Xanthines | 1 | 1984 | 19 | 0.000 |
Why?
| Radioligand Assay | 1 | 1984 | 48 | 0.000 |
Why?
| Tritium | 1 | 1984 | 75 | 0.000 |
Why?
| Guanosine Triphosphate | 1 | 1984 | 92 | 0.000 |
Why?
| Magnesium | 1 | 1984 | 153 | 0.000 |
Why?
| Sodium | 1 | 1984 | 206 | 0.000 |
Why?
| Vasodilator Agents | 1 | 1984 | 326 | 0.000 |
Why?
| Calcium | 1 | 1984 | 1213 | 0.000 |
Why?
|
|
Poeschla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|